Reply:
Anna Ludovica Fracanzani, Luca Valenti, Silvia Fargion – 28 January 2009
Delayed splenic artery occlusion for treatment of established small‐for‐size syndrome after partial liver transplantation
Abhinav Humar, Joy Beissel, Shaina Crotteau, Melissa Cohen, John Lake, William D. Payne – 28 January 2009 – We looked at the impact of delayed splenic artery occlusion (SAO) on recipients with established small‐for‐size syndrome (SFSS) after partial graft liver transplantation [either from a living donor (LD) or split from a deceased donor (DD)]. Between 1999 and 2007 we performed a total of 100 partial liver transplantations in adult recipients: 66 LD transplantations and 34 DD split transplantations.
The genes that underlie fatty liver disease: The harvest has begun
Ralf Weiskirchen, Hermann E. Wasmuth – 28 January 2009
The optimal ribavirin dose for patients infected with hepatitis C virus genotype 3: Should we utilize more?
Alessio Aghemo, Maria Grazia Rumi, Gian Maria Prati, Massimo Colombo – 28 January 2009
Occult hepatitis C: How convincing are the current data?
Martin‐Walter Welker, Stefan Zeuzem – 28 January 2009
Serum M30 levels: A potential biomarker of severe liver disease in nonalcoholic fatty liver disease and normal aminotransferase levels
Yusuf Yilmaz, Engin Ulukaya, Enver Dolar – 28 January 2009
The interleukin‐17 pathway is involved in human alcoholic liver disease
Arnaud Lemmers, Christophe Moreno, Thierry Gustot, Raphaël Maréchal, Delphine Degré, Pieter Demetter, Patricia de Nadai, Albert Geerts, Eric Quertinmont, Vincent Vercruysse, Olivier Le Moine, Jacques Devière – 28 January 2009 – Immune dysregulations in alcoholic liver diseases are still unclear, especially regarding alcoholic hepatitis inflammatory burst. Interleukin‐17 (IL‐17) is known to enhance neutrophil recruitment. We studied the IL‐17 pathway in alcoholic cirrhosis and alcoholic hepatitis.
Determinants of relapse after a short (12 weeks) course of antiviral therapy and re‐treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection
Alessandra Mangia, Nicola Minerva, Donato Bacca, Raffaele Cozzolongo, Ernesto Agostinacchio, Fernando Sogari, Gaetano Scotto, Francesco Vinelli, Giovanni Luciano Ricci, Mario Romano, Vito Carretta, Daniela Petruzzellis, Angelo Andriulli – 28 January 2009 – In hepatitis C virus (HCV) genotypes 2 and 3 patients, the high rate of relapse after 12 to 16 weeks of antiviral therapy is the main concern for shortening treatment duration.
Profiling microRNA expression: A snapshot of nonalcoholic steatohepatitis and a recording of its pathogenesis
Anna Alisi, Andrea Masotti, Valerio Nobili – 28 January 2009
Systematic review on preventing bacterial sepsis and wound complications in liver transplant patients
James D. Perkins – 28 January 2009